Hepatitis C - Pipeline Review, H2 2015

Hepatitis C - Pipeline Review, H2 2015

Code: GMDHC6822IDB | Published: Dec-2015 | Pages: 598 | Global Markets Direct
Price :

* Required Fields



Hepatitis C - Pipeline Review, H2 2015


Global Markets Directs, Hepatitis C - Pipeline Review, H2 2015, provides an overview of the Hepatitis Cs therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
3-V Biosciences, Inc.
AbbVie Inc.
AiCuris GmbH & Co. KG
AIMM Therapeutics B.V.
Akshaya Bio Inc.
Altor BioScience Corporation
Amarillo Biosciences, Inc.
Amarna Therapeutics B.V.
ARA Healthcare Pvt. Ltd.
Arbutus Biopharma Corporation
Arrowhead Research Corporation
Astex Pharmaceuticals, Inc.
Benitec Biopharma Limited
Biogenomics Limited
BioLineRx, Ltd.
Bionor Pharma ASA
Biota Pharmaceuticals, Inc.
Biotest AG
Biotron Limited
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chugai Pharmaceutical Co., Ltd.
Cocrystal Pharma, Inc.
Conatus Pharmaceuticals Inc.
Debiopharm International S.A.
Delpor, Inc.
Digna Biotech, S.L.
DiscoveryBiomed, Inc.
Enanta Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Formune S.L.
Genecode AS
GeneCure LLC
Gilead Sciences, Inc.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Hepacyl Therapeutics, SL
Hependo Sp. z o. o. (Ltd)
ImmunoBiology Limited
Immunocore Limited
Immunomedics, Inc.
Inbiopro Solutions Pvt. Ltd.
Inovio Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
iTherX, Inc.
JN-International Medical Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kineta, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Medivir AB
Merck & Co., Inc.
Microbio Co., Ltd.
Microbiotix, Inc.
MultiCell Technologies, Inc.
Myelo Therapeutics GmbH
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
Polaris Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Regulus Therapeutics Inc.
Rodos BioTarget GmbH
Savoy Pharmaceuticals, Inc.
SEEK Group
SKAU Vaccines ApS
SomaGenics Inc.
Sorrento Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd.
Therapix Biosciences Ltd
Therapure Biopharma Inc.
Theravectys SA
Vakzine Projekt Management GmbH
VBI Vaccines Inc.
Vertex Pharmaceuticals Incorporated
ViroLogik GmbH
WaterStone Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients